GSTM1 and colorectal neoplasm: Additional advantages of FIT include the possibility of high-throughput automated processing as well as user-friendly application and higher adherence.7,13,14,25,26 Our results demonstrate that, at comparable positivity rates (6.0% for gFOBT vs. 7.7% for FIT), gFOBT is much less sensitive than FIT for clinically relevant colorectal neoplasms, which suggests that programmes switching from gFOBT to FIT will achieve better outcomes, even if using a FIT positivity threshold (at 15 μg Hb/g cut-off) that yields similar positivity rates as the gFOBT.